CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
CG Oncology (NASDAQ: CGON) announced its participation in the 120th American Urological Association (AUA) Annual Meeting, scheduled for April 26-29, 2025, in Las Vegas. The company will present significant updates on their bladder cancer therapeutic cretostimogene grenadenorepvec.
The highlight will be the presentation of BOND-003 study durability results as a late-breaking announcement during the Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s) session. This study focuses on cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer.
The company will showcase multiple presentations including:
- Translational correlates using urinary genomic disease burden analysis
- Updates to the CORE-008 trial protocol
- Progress updates on BOND-003 Cohort P study
- Details on the Phase 3 PIVOT-006 randomized study
CG Oncology (NASDAQ: CGON) ha annunciato la sua partecipazione al 120° Congresso Annuale dell'American Urological Association (AUA), in programma dal 26 al 29 aprile 2025 a Las Vegas. L'azienda presenterà aggiornamenti significativi sulla loro terapia per il cancro alla vescica cretostimogene grenadenorepvec.
Il momento clou sarà la presentazione dei risultati di durata dello studio BOND-003 come annuncio dell'ultimo minuto durante la sessione sui Trial Clinici che Cambiano la Pratica e Trasformano i Paradigmi in Urologia (P2s). Questo studio si concentra sulla monoterapia con cretostimogene nel cancro alla vescica non muscolo invasivo ad alto rischio non responsivo al BCG.
L'azienda presenterà diverse relazioni tra cui:
- Correlati traslazionali utilizzando l'analisi del carico di malattia genomica urinaria
- Aggiornamenti al protocollo dello studio CORE-008
- Aggiornamenti sui progressi dello studio BOND-003 Coorte P
- Dettagli sullo studio randomizzato di Fase 3 PIVOT-006
CG Oncology (NASDAQ: CGON) anunció su participación en la 120ª Reunión Anual de la Asociación Americana de Urología (AUA), programada para el 26 al 29 de abril de 2025 en Las Vegas. La compañía presentará actualizaciones significativas sobre su terapia para el cáncer de vejiga cretostimogene grenadenorepvec.
El punto culminante será la presentación de los resultados de durabilidad del estudio BOND-003 como un anuncio de última hora durante la sesión de Ensayos Clínicos que Cambian la Práctica y Transforman Paradigmas en Urología (P2s). Este estudio se centra en la monoterapia con cretostimogene en cáncer de vejiga no musculoinvasivo de alto riesgo que no responde al BCG.
La compañía mostrará múltiples presentaciones, incluyendo:
- Correlatos traslacionales utilizando el análisis de carga de enfermedad genómica urinaria
- Actualizaciones al protocolo del ensayo CORE-008
- Actualizaciones sobre el progreso del estudio BOND-003 Cohorte P
- Detalles sobre el estudio aleatorizado de Fase 3 PIVOT-006
CG Oncology (NASDAQ: CGON)는 2025년 4월 26일부터 29일까지 라스베이거스에서 열리는 제120회 미국 비뇨기과 학회(AUA) 연례 회의에 참여할 것이라고 발표했습니다. 이 회사는 방광암 치료제인 cretostimogene grenadenorepvec에 대한 중요한 업데이트를 발표할 예정입니다.
주요 발표는 BOND-003 연구의 내구성 결과로, 비뇨기과의 임상 시험에서의 실천 변화 및 패러다임 전환(P2s) 세션 중에 마지막 발표로 진행될 것입니다. 이 연구는 BCG에 반응하지 않는 고위험 비근육 침습성 방광암에서의 cretostimogene 단독 요법에 중점을 두고 있습니다.
회사는 다음과 같은 여러 발표를 선보일 예정입니다:
- 소변 유전자 질병 부담 분석을 통한 전이적 상관관계
- CORE-008 시험 프로토콜 업데이트
- BOND-003 코호트 P 연구의 진행 상황 업데이트
- 3상 PIVOT-006 무작위 연구에 대한 세부 사항
CG Oncology (NASDAQ: CGON) a annoncé sa participation à la 120e Réunion Annuelle de l'American Urological Association (AUA), prévue du 26 au 29 avril 2025 à Las Vegas. L'entreprise présentera des mises à jour significatives sur leur thérapie contre le cancer de la vessie cretostimogene grenadenorepvec.
Le point culminant sera la présentation des résultats de durabilité de l'étude BOND-003 comme une annonce de dernière minute lors de la session sur les essais cliniques qui changent la pratique et transforment les paradigmes en urologie (P2s). Cette étude se concentre sur la monothérapie avec le cretostimogene dans le cancer de la vessie non musculo-invasif à haut risque non réactif au BCG.
L'entreprise présentera plusieurs présentations, y compris:
- Corrélats translationnels utilisant une analyse de la charge génomique urinaire de la maladie
- Mises à jour du protocole de l'essai CORE-008
- Mises à jour sur les progrès de l'étude BOND-003 Cohorte P
- Détails sur l'étude randomisée de Phase 3 PIVOT-006
CG Oncology (NASDAQ: CGON) gab seine Teilnahme an der 120. Jahrestagung der American Urological Association (AUA) bekannt, die vom 26. bis 29. April 2025 in Las Vegas stattfinden wird. Das Unternehmen wird bedeutende Updates zu seiner Therapie gegen Blasenkrebs cretostimogene grenadenorepvec präsentieren.
Ein Höhepunkt wird die Präsentation der Haltbarkeitsresultate der BOND-003-Studie als späte Ankündigung während der Sitzung über praxisverändernde, paradigmatische klinische Studien in der Urologie (P2s) sein. Diese Studie konzentriert sich auf die Monotherapie mit cretostimogene bei hochriskantem, BCG-unempfindlichem, nicht muskelinvasivem Blasenkrebs.
Das Unternehmen wird mehrere Präsentationen zeigen, darunter:
- Translationalkorrelate mittels urinärer genomischer Krankheitslastanalyse
- Updates zum CORE-008 Studienprotokoll
- Fortschrittsupdates zur BOND-003 Kohorte P Studie
- Details zur Phase-3 PIVOT-006 randomisierten Studie
- None.
- None.
- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology -
- Additional updates from across CG Oncology’s clinical trial program, including translational data, planned -
IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced BOND-003 study of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer has been selected as a late breaker as part of American Urological Association (AUA)’s Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s). Designed to showcase the exceptional, groundbreaking studies that are expected to change the day-to-day practice of urology, P2s are reserved for the most impactful studies and will be presented on the Plenary stage. Additionally, CG Oncology will present updates to ongoing clinical trials evaluating cretostimogene across the non-muscle invasive bladder cancer (NMIBC) treatment landscape which are expected to influence urology practice, as well as one interactive poster on translational data. The AUA Annual Meeting, scheduled from April 26-29, 2025, in Las Vegas, Nevada, is the largest gathering of urologists in the world, where leaders in the field share groundbreaking research, new guidelines and the latest advances in urologic medicine.
CG Oncology will have a series of key presentations and updates on cretostimogene grenadenorepvec including:
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ
Session: Saturday Morning Plenary Session
Presenter: Mark D. Tyson, MD, MPH; Urologic Oncologist in the Department of Urology at Mayo Clinic in Phoenix, Arizona
Presentation Date & Time: Saturday, April 26, 2025, 10:40 AM to 10:50 AM PT
Location: Venetian Ballroom, The Venetian Convention & Expo Center
IP02-28: Translational Correlates using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Updated Analysis from the BOND-003 and CORE-001 Trials
Session: IP02- Bladder Cancer- Non-Invasive I
Presenter: Colin P. N. Dinney, MD; Professor and Chairman of the Department of Urology at The University of Texas M D Anderson Cancer Center
Presentation Date & Time: Saturday, April 26, 2025, 7:00 AM to 9:00 AM PT
Location: Marco Polo 701, The Venetian Convention & Expo Center
Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer
Session: Clinical Trials in Progress- Bladder Cancer
Presenter: Trinity J. Bivalacqua, MD, PhD Professor of Urology and Oncology at the University of Pennsylvania
Presentation Date & Time: Monday, April 28, 2025, 9:56 AM to 10:04 AM PT
Location: Learning Lab, The Venetian Convention & Expo Center
Trial in Progress: BOND-003 Cohort P- A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Session: Clinical Trials in Progress- Bladder Cancer
Presenter: Mark D. Tyson, MD, MPH; Urologic Oncologist in the Department of Urology at Mayo Clinic in Phoenix, Arizona
Presentation Date & Time: Monday, April 28, 2025, 9:40 AM to 9:48 AM PT
Location: Learning Lab, The Venetian Convention & Expo Center
Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Session: Clinical Trials in Progress- Bladder Cancer
Presenter: Max Kates, MD, Associate Professor of Urology and Oncology and Director of the Bladder Cancer Program in the Brady Urological Institute at Johns Hopkins
Presentation Date & Time: Monday, April 28, 2025, 10:28 AM to 10:36 AM PT
Location: Learning Lab, The Venetian Convention & Expo Center
About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. Cretostimogene is also being evaluated in a Phase 3 monotherapy clinical trial (PIVOT-006) in patients with intermediate-risk NMIBC. In addition, cretostimogene is being evaluated in an investigator-sponsored clinical trial in combination with nivolumab for the treatment of muscle invasive bladder cancer.
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Chau Cheng
Vice President, Investor Relations, CG Oncology
(949) 342-8939
chau.cheng@cgoncology.com
FAQ
What are the key findings being presented for CGON's BOND-003 study at AUA 2025?
When and where will CGON present at the 2025 AUA Annual Meeting?
What clinical trials will CGON provide updates on at AUA 2025?
Who are the key presenters for CGON's research at AUA 2025?
What is the significance of CGON's presentation being selected for P2s at AUA 2025?
